NEW YORK (GenomeWeb) – Sequenom has secured a national coverage agreement with UnitedHealthcare for its prenatal diagnostic tests.
The agreement covers Sequenom's noninvasive prenatal test, MaterniT21 Plus and also its universal and cystic fibrosis carrier screening tests, HerediT Universal and HerediT CF. It will go into effect Oct. 1 and will cover 43 million people throughout the US.
Including the agreement with UnitedHealthcare, Sequenom now has more than 200 million lives covered under contract.
The agreement does not include Sequenom's newer offerings — its VisibiliT test for screening women with average-risk pregnancies for trisomies 21 and 18; or its MaterniT Genome, a noninvasive test that analyzes chromosomal loss or duplication of greater than 7 megabases across the entire genome.